RT Journal Article
SR Electronic
T1 Predicting Onset of COVID-19 with Mobility-Augmented SEIR Model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.27.20159996
DO 10.1101/2020.07.27.20159996
A1 Neo Wu
A1 Xue Ben
A1 Bradley Green
A1 Kathryn Rough
A1 Srinivasan Venkatramanan
A1 Madhav Marathe
A1 Paul Eastham
A1 Adam Sadilek
A1 Shawn O’Banion
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.07.27.20159996.abstract
AB Timely interventions and early preparedness of healthcare resources are crucial measures to tackle the COVID-19 disease. To aid these efforts, we developed the Mobility-Augmented SEIR model (MA-SEIR) that leverages Google’s aggregate and anonymized mobility data to augment classic compartmental models. We show in a retrospective analysis how this method can be applied at an early stage in the COVID-19 epidemic to forecast its subsequent spread and onset in different geographic regions, with minimal parameterization of the model. This provides insight into the role of near real-time aggregate mobility data in disease spread modeling by quantifying substantial changes in how populations move both locally and globally. These changes would be otherwise very hard to capture using less timely data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data are anonymized and sufficiently aggregated.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe do not share any data.